Bogumil Walter Form 4 March 04, 2019

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box subject to

if no longer Section 16. Form 4 or

Form 5 obligations may continue. See Instruction STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

SeaWorld Entertainment, Inc.

3. Date of Earliest Transaction

4. If Amendment, Date Original

Filed(Month/Day/Year)

Symbol

[SEAS]

(Month/Day/Year)

02/28/2019

(Print or Type Responses)

1(b).

(City)

1. Name and Address of Reporting Person * **Bogumil Walter**

> (Last) (First) (Middle)

C/O SEAWORLD ENTERTAINMENT, INC., 9205 SOUTHPARK CENTER LOOP, SUITE 400

(Street)

ORLANDO, FL 32819

(Zip)

(Address of principal executive offices)

(State)

Registrant's telephone number, including area code: (732) 545-1590

Not applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per

response...

0.5

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

Director 10% Owner

X_ Officer (give title Other (specify below)

Chief Strategy Officer

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.02 Unregistered Sales of Equity Securities.

On November 15, 2010, Advaxis, Inc. (the "Company") issued and sold 61 shares of non-convertible, redeemable Series B preferred stock ("Series B Preferred Stock") to Optimus Life Sciences Capital Partners LLC (the "Investor") pursuant to the terms of a Preferred Stock Purchase Agreement between the Company and the Investor dated July 19, 2010 (the "Purchase Agreement"). The aggregate purchase price for the shares of Series B Preferred Stock was \$610,000. Under the terms of the Purchase Agreement, the Investor remains obligated, from time to time until July 19, 2013, to purchase up to an additional 400 shares of Series B Preferred Stock at a purchase price of \$10,000 per share upon notice from the Company to the Investor, and subject to the satisfaction of certain conditions, as set forth in the Purchase Agreement.

The Series B Preferred Stock was offered and sold in a private placement transaction made in reliance upon exemptions from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D promulgated thereunder.

Item 8.01 Other Events.

In connection with the issuance by the Company of the Series B Preferred Stock described above, an affiliate of the Investor exercised a warrant to purchase 5,312,903 shares of the Company's common stock, \$0.001 par value (the "Common

Edgar Filing: Bogumil Walter - Form 4

Stock") at an exercise price of \$0.155 per share. As permitted by the terms of such warrant, the aggregate exercise price of \$823,500 received by the Company is payable pursuant to a four-year full recourse promissory note bearing interest at the rate of 2% per year.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: NovemberAdvaxis, Inc. 16, 2010

By: /S/ Mark J.
Rosenblum
Mark J.
Rosenblum
Chief
Financial
Officer and
Secretary